Keyphrases
Adverse Effects
9%
Ankle Edema
9%
Association Criterion
12%
Blood Glucose
9%
Clinical Staff
12%
Conventional Therapy
9%
Cost-benefit
9%
Cost-effectiveness
18%
Cutaneous Lupus Erythematosus
12%
Diabetes
9%
Diagnostic Evaluation
100%
Direct Costs
9%
Direct Immunofluorescence
12%
Discoid Lupus Erythematosus
100%
Double-blind Randomized Controlled Trial
9%
Fructosamine
27%
Glycemic Control
45%
Glycemic Status
9%
Histopathological Examination
12%
Histopathology Laboratory
12%
Hypoglycemia
9%
Hypoglycemic Episodes
18%
Hypoglycemic Events
18%
Lesional Skin
12%
Lupus Band Test
100%
Muslims
100%
Negative Predictive Value
37%
No Significant Difference
9%
Once-daily
9%
Oral Hypoglycemic Agents
45%
Pioglitazone
100%
Placebo
18%
Placebo Groups
9%
Positive Predictive Value
25%
Predictive Value
12%
Ramadan
100%
Rheumatism
12%
Sensitivity Specificity
12%
Systemic Lupus Erythematosus
100%
Type 2 Diabetes Mellitus (T2DM)
18%
Weight Gain
9%
Medicine and Dentistry
Diagnosis
100%
Discoid Lupus Erythematosus
100%
Disease
11%
Histopathology
22%
Immunofluorescence Test
11%
Laboratory Test
11%
Lupus Band Test
100%
Rheumatic Disease
11%
Sensitivity and Specificity
11%
Subacute Cutaneous Lupus Erythematosus
11%
Systemic Lupus Erythematosus
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Ankle Edema
9%
Antidiabetic Agent
36%
Fructosamine
27%
Hypoglycemia
9%
Non Insulin Dependent Diabetes Mellitus
18%
Oral Antidiabetic Agent
45%
Pioglitazone
100%
Placebo
27%
Randomized Controlled Trial
9%